Arcturus Therapeutics Ltd (ARCT) Stock Price, Quote & News

Company Profile

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 900 2660

Website: arcturusrx.com

Address:

10285 Science Center Drive, San Diego, United States

bigchouse Feb. 4 at 3:56 AM

$ARCT Terrifying discovery as cops raid suspected biolab in Las Vegas with thousands of vials Newly released footage from the Las Vegas Metropolitan Police Department shows a dramatic hazmat response as agents hauled bags of medical tubing, vials and containers filled with unknown liquids from the suburban property. https://www.dailymail.co.uk/sciencetech/article-15524491/chinese-biolab-Las-Vegas-california.html

0 · Reply

bigchouse Feb. 3 at 6:20 PM

$ARCT Buy more.

0 · Reply

bigchouse Feb. 2 at 7:25 PM

$ARCT FBI and Metro Police Raid Illegal Bio Lab in Las Vegas The FBI and Metro Police raided an illegal biological lab in Las Vegas on Saturday morning. The bio lab in Vegas is possibly linked to another illegal lab under investigation in Fresno, California, where authorities found deadly viruses such as HIV, Covid and Ebola. https://www.8newsnow.com/investigators/las-vegas-bio-lab-raid-possibly-tied-to-california-case-federal-chinese-investigation/

0 · Reply

Newbilly Feb. 2 at 4:45 PM

$ARCT Getting

0 · Reply

bigchouse Feb. 2 at 4:17 PM

$ARCT Reverse the A logo and you get an X logo.

0 · Reply

bigchouse Feb. 2 at 4:14 PM

$ARCT $AI C3.ai Inc has been crashing the past year. That stock is a shorts' paradise.

0 · Reply

Dubthesaxguy Feb. 2 at 4:25 AM

$ARCT This may be an interesting reason for a pop. https://www.ad-hoc-news.de/boerse/news/ueberblick/arcturus-therapeutics-reaches-key-clinical-trial-milestone/68540921

0 · Reply

bigchouse Jan. 30 at 1:55 PM

$ARCT

0 · Reply

wahoowa96 Jan. 29 at 2:15 PM

$ARCT Go short all AI's tech's Google Microsoft Credo TSMC. Their main goal was to contribute to drug discovery in rare diseases...Are they really helping out biotech sector? None they are just discouraging investors from going into biotech...but asking them to put the money on the debt-inflatef growth.

0 · Reply

wahoowa95 Jan. 28 at 7:00 PM

$ARCT saw Joe Payne walk into Abbvie yesterday with a Briefcase. The deal is almost complete! Inshallah

0 · Reply

Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 24, 2025, 4:01 PM EST - 2 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conference

Nov 10, 2025, 9:01 PM EST - 3 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:01 PM EST - 3 months ago

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

Nov 4, 2025, 4:01 PM EST - 3 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Oct 28, 2025, 4:01 PM EDT - 3 months ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

Oct 22, 2025, 3:05 PM EDT - 3 months ago

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture

Oct 22, 2025, 8:53 AM EDT - 3 months ago

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

Oct 22, 2025, 7:30 AM EDT - 3 months ago

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

Aug 11, 2025, 8:16 PM EDT - 6 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Jul 24, 2025, 4:01 PM EDT - 6 months ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jun 30, 2025, 11:00 AM EDT - 7 months ago

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Jun 23, 2025, 8:30 AM EDT - 8 months ago

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

May 12, 2025, 7:40 PM EDT - 9 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 9 months ago

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Apr 22, 2025, 4:01 PM EDT - 10 months ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Apr 10, 2025, 8:00 AM EDT - 10 months ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Mar 6, 2025, 9:44 PM EST - 11 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:01 PM EST - 11 months ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 5, 2025, 4:30 PM EST - 11 months ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Feb 24, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 14, 2025, 8:30 AM EST - 1 year ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 4, 2025, 8:30 AM EST - 1 year ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Jan 31, 2025, 3:00 AM EST - 1 year ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 30, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 10, 2025, 8:00 AM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 6, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Dec 16, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 18, 2024, 8:00 PM EST - 1 year ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 1:44 PM EST - 1 year ago

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14, 2024, 1:00 AM EST - 1 year ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 11, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 7, 2024, 11:24 PM EST - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 13, 2024, 8:15 AM EDT - 1 year ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Aug 27, 2024, 5:00 PM EDT - 1 year ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 9, 2024, 5:27 AM EDT - 1 year ago

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 5, 2024, 8:50 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 7:30 PM EDT - 1 year ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Jun 8, 2024, 2:42 AM EDT - 1 year ago

Arcturus: A Hidden Gem In The Biotech Sector

Jun 7, 2024, 10:30 AM EDT - 1 year ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

bigchouse Feb. 4 at 3:56 AM

0 · Reply

bigchouse Feb. 3 at 6:20 PM

$ARCT Buy more.

0 · Reply

bigchouse Feb. 2 at 7:25 PM

0 · Reply

Newbilly Feb. 2 at 4:45 PM

$ARCT Getting

0 · Reply

bigchouse Feb. 2 at 4:17 PM

$ARCT Reverse the A logo and you get an X logo.

0 · Reply

bigchouse Feb. 2 at 4:14 PM

$ARCT $AI C3.ai Inc has been crashing the past year. That stock is a shorts' paradise.

0 · Reply

Dubthesaxguy Feb. 2 at 4:25 AM

$ARCT This may be an interesting reason for a pop. https://www.ad-hoc-news.de/boerse/news/ueberblick/arcturus-therapeutics-reaches-key-clinical-trial-milestone/68540921

0 · Reply

bigchouse Jan. 30 at 1:55 PM

$ARCT

0 · Reply

wahoowa96 Jan. 29 at 2:15 PM

0 · Reply

wahoowa95 Jan. 28 at 7:00 PM

$ARCT saw Joe Payne walk into Abbvie yesterday with a Briefcase. The deal is almost complete! Inshallah

0 · Reply

Den00 Jan. 28 at 6:18 PM

$ARCT volatility is down, nice hammers forming, this is ready for a move upwards or downwards!

0 · Reply

wahoowa95 Jan. 27 at 11:43 PM

$ARCT man this blizzard is killing me

1 · Reply

wahoowa95 Jan. 27 at 6:30 PM

$ARCT big payout soon from Abbvie

0 · Reply

bigchouse Jan. 27 at 4:45 PM

$ARCT Human outbreaks of Nipah virus have only been identified in South and South-East Asia, primarily in rural or semi-rural locations. Countries with previously reported outbreaks include: Bangladesh (where cases have occurred almost annually since 2001) India (including outbreaks in Kerala in Southern India since 2018, and a current outbreak in West Bengal) Malaysia The Philippines Singapore

0 · Reply

Morechange Jan. 27 at 2:27 PM

$ARCT i think things will be good today

0 · Reply

bigchouse Jan. 26 at 8:21 PM

$ARCT Officials reinstate Covid-era monitoring and quarantines after outbreak of deadly virus that has no cure Several airports across Asia have stepped up precautionary measures after India's West Bengal region confirmed five cases of Nipah virus, which is carried by bats and infects both pigs and humans. https://www.dailymail.co.uk/health/article-15498755/officials-covid-quarantines-nipah-virus-india-outbreak.html

0 · Reply

bigchouse Jan. 24 at 1:26 PM

$ARCT Arcturus Therapeutics, Inc. v. AbbVie Inc. et al (Case No. 3:25-cv-02494) Recent Filings: The court granted the extension on December 8, 2025, setting a new deadline for Arcturus to file its response in opposition to AbbVie’s motion to dismiss by January 22, 2026. Arcturus filed its response in opposition on January 22, 2026, as required. AbbVie is now scheduled to file a reply by February 12, 2026.

1 · Reply

notreload_ai Jan. 22 at 10:09 PM

Roth Capital initiates coverage of $ARCT with a Buy rating and $20 price target, citing undervaluation and strong rare disease pipeline potential. https://notreload.xyz/roth-capital-starts-coverage-on-arcturus-therapeutics-with-buy-rating/

0 · Reply

wahoowa96 Jan. 22 at 3:50 PM

$ARCT Didn't Japanese partner Meiji Seka have work cut out for sa mRNA-LNP cancer vaccines? Why MRK+MRNA so excited like seeing it first time?

1 · Reply

wahoowa96 Jan. 22 at 3:46 PM

$ARCT I think Moderna's mRNA-LNP based cancer vaccines will need self-amplifying feature of Arcturus and capabilities to be stored in room temperature because to there's a dose related risk concerns at the end of the day if the lipids are not degrading fast enough.

1 · Reply

MaxCorona Jan. 22 at 3:24 PM

$ARCT bought yesterday another 500 for 7,11$.

0 · Reply

Newbilly Jan. 22 at 3:13 PM

$ARCT

0 · Reply

Market Cap	212.25M
Revenue (ttm)	152.31M
Net Income (ttm)	-80.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-53.14%
Debt to Equity Ratio	0.00

Volume	602,700
Avg Vol	642,960
Day's Range	N/A - N/A
Shares Out	28.41M
Stochastic %K	18%
Beta	2.24
Analysts	Strong Sell
Price Target	$29.25